ReCon Chat with Bob...
Health Care: Drugs
Alkermes PLC (ALKS: NASDAQ)
$32.84 -0.16 | -0.48%
05/24/13 - 04:00 PM ET
Company Cash Flow
| Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -113.68M | -45.54M | -39.63M | 130.50M |
| Operating Gains/Losses | 0.00 | 841.00K | 94.00K | 3.71M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -14.01M | 2.35M | -728.00K | 13.71M |
| (Increase) Decrease in Inventories | -4.88M | 5.21M | -4.04M | -5.14M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 11.22M | 6.95M | -2.06M | 2.01M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 6.58M | -6.06M | -8.57M | -133.55M |
| Other Non-Cash Items | 33.17M | 21.69M | 17.66M | 13.08M |
| Net Cash From Continuing Operations | -2.48M | -5.91M | -12.25M | 34.59M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -2.48M | -5.91M | -12.25M | 34.59M |
| Sale of Property, Plant & Equipment | 35.00K | 395.00K | 248.00K | 7.72M |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -16.99M | -9.40M | -15.79M | -5.50M |
| Acquisitions | -494.77M | 0.00 | -8.00M | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 385.51M | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -417.16M | 5.63M | 28.01M | 45.36M |
| Issuance of Debt | 444.10M | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 17.19M | 4.74M | 2.59M | 7.06M |
| Repayment of Long-Term Debt | -775.00K | -45.40M | -23.49M | -83.44M |
| Repurchase of Capital Stock | 0.00 | 0.00 | -2.68M | -18.00M |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 4.34M | 0.00 | 246.00K | 80.00K |
| Net Cash From Financing Activities | 464.85M | -40.65M | -23.33M | -94.30M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 45.21M | -40.93M | -7.57M | -14.35M |
Portfolios with ALKS
- Portfolio NameUser Type
- ContributorTechnical Setups for the We...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- UserInvestments
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Usergterryburns
- Usermitetwo Portfolio 1
Latest ALKS Headlines from TheStreet
- ALKS July Options Begin Trading 05.20.13 | 02:05 pm
- Alkermes Stock Hits New 52-Week High (ALKS) 05.20.13 | 10:05 am
- SALT 2013: The 5 Best Ideas of the Year Ahead 05.10.13 | 04:05 pm
- Alkermes Stock Hits New 52-Week High (ALKS) 04.19.13 | 02:04 pm
- Cramer's 6 Stocks in 60 Seconds: LDK ALKS APA BBY UNP HFC (Update 1) 04.18.13 | 05:04 pm
- 3 Stocks Advancing The Health Care Sector 04.17.13 | 01:04 pm
- Three Cheers For Alkermes Running A Depression Study In The US of A 04.17.13 | 10:04 am
- Alkermes Stock Gaps Up On Today's Open (ALKS) 04.17.13 | 10:04 am
- Cramer's 6 Stocks in 60 Seconds: EA BTU ALKS SLB PEP SWN (Update 1) 03.26.13 | 05:03 pm
- Alkermes: A Biotech With Multiple Drivers
02.28.13 | 11:02 am
Press Releases for ALKS
- Alkermes’ Corporate Presentation To Be Webcast At Three Upcoming Conferences - Business Wire 02.19.13 | 04:02 pm
- Alkermes’ Corporate Presentation To Be Webcast At Two Upcoming Conferences - Business Wire 02.05.13 | 04:02 pm
- Alkermes Plc Reports Third Quarter Fiscal 2013 Financial Results - Business Wire 01.31.13 | 07:01 am
- Alkermes To Host Conference Call To Discuss Financial Results For Third Quarter Of Fiscal 2013 - Business Wire 01.24.13 | 04:01 pm
- Alkermes Announces Notice Of Allowance Of Key U.S. Patent For Aripiprazole Lauroxil, A New Schizophrenia Drug Candidate - Business Wire 01.03.13 | 07:01 am
- Alkermes Expands CNS Pipeline And Announces Positive Results From Phase 1 Study Of ALKS 3831, A Novel Antipsychotic Therapy For The Treatment Of Schizophrenia - Business Wire 01.03.13 | 07:01 am
- Alkermes’ Corporate Presentation To Be Webcast At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 01.02.13 | 04:01 pm
- Alkermes And Collaborators To Present Data From Three Ongoing Clinical Development Programs At Two Major Medical Meetings - Business Wire 12.03.12 | 07:12 am
- Alkermes’ Corporate Presentation To Be Webcast At Two Upcoming Conferences - Business Wire 11.07.12 | 04:11 pm
- Alkermes Plc Reports Second Quarter Fiscal 2013 Financial Results - Business Wire 11.01.12 | 07:11 am
Partner Headlines for ALKS
- Alkermes Leaps On Study Results, May Offer New Entry - Investor's Business Daily 04.17.13 | 05:04 pm
- Indexes Notch Sharp Declines; New 52-Week Low For Apple - Investor's Business Daily 04.17.13 | 04:04 pm
- Stocks Hold Near Lows, But Alkermes Soars To New High - Investor's Business Daily 04.17.13 | 03:04 pm
- Biotech Alkermes Poised To Swell On Pipeline Wins - Investor's Business Daily 04.16.13 | 05:04 pm
- Pockets of Strength In Top Groups, Few Leaders Basing - Investor's Business Daily 04.15.13 | 06:04 pm
- Alkermes Aims At Bipolar, Addiction Markets To Grow - Investor's Business Daily 04.15.13 | 04:04 pm
- Biotech Watch-List: Medicine Co., Alkermes, Celgene - Investor's Business Daily 03.11.13 | 05:03 pm
- Foreign Stocks Also Fall In A Correction - Investor's Business Daily 02.26.13 | 05:02 pm
- Alkermes Finding Support At 10-Week Average - Investor's Business Daily 02.21.13 | 05:02 pm
- Stocks Hold Near Session Lows; Generac Stumbles - Investor's Business Daily 02.21.13 | 03:02 pm
